Essential payer insights

Using real world evidence in clinical trials is critical to the success of patient recruitment and payer engagement programs. Through more stakeholder collaboration, we can help patients access the right treatment for them. How can we achieve this in practice? How do we overcome pricing and funding challenges? How can we use data better? We put these important questions to …

Patient, Registries, Evidence, Value, Evidence Europe

How can patient registries add value to evidence based decision making?

At Evidence EU 2014, Dr. Päivi Hämäläinen, Director of Department of Information, National Institute of Health and Welfare, Finland, gave a presentation “How can patient registries add value to evidence based decision making?” Dr. Päivi Hämäläinen’s presentation depicts her theoretical vision: data is created during patient visits to care and can be secondarily used for research, planning and decision making. Download and …

Disease, Value, Registries, Decision making, Evidence, Evidence Europe

How Can Disease Registries Add Value to Evidence Based Decision Making?

At Evidence EU 2014, Steve Cunningham Consultant & Honorary Reader in Paediatric Respiratory Medicine, NHS, gave a presentation on “How Can Disease Registries Add Value to Evidence Based Decision Making?” Download and learn:  Case Identifier Registry Detailed Case Registry Large Disease Registry Current Definitions of Evidence Quality Evidence Quality -GRADE System Detailed Observational Data Download presentation Found this interesting? Join us at …

insights, ebook, evidence, real world evidence, rwe, evidence europe 2015

Ebook: Essential insights into real world evidence

Successful companies need to incorporate real world evidence in clinical trials, post approval studies and in payer engagement programmes. Needless to say, this shift is causing monumental changes in how the industry operates, how the payers engage with them and how service providers support pharma. This raises some important questions. What is value? What parts of our existing business model do we keep and what …

value, assessment

From promise to reality: how is real world evidence shaping the future of healthcare?

At Evidence EU  2014, David Haslam, Chairman NICE gave a presentation on “From promise to reality: how is real world evidence shaping the future of healthcare?” This presentation explores NICE’s role in improving outcomes for people as well as focusing on challenges (uptake, implementation and pushy patients) and value-based assessment. Download and learn: The multi morbidity challenge Value Based Assessment …

Value, European, Healthcare, Market

How to develop a compelling value proposition in the current European healthcare market

At Evidence EU 2014, Caroline Gadd, Otsuka Pharmaceuticals, gave a presentation on “How to develop a compelling value proposition in the current European healthcare market”. Gadd’s presentation highlights the importance of value proposition, demonstrating that a successful proposition is moving towards a customer centric approach as well as being able to support the whole market. Download and Learn: The value proposition as …

patient, outcomes

How can patient reported outcomes generate evidence to validate health claims?

At Evidence EU 2014, Tara Symonds , Senior Director, Pfizer, gave a presentation on  “How can patient reported outcomes generate evidence to validate health claims?” Symonds’ presentation reveals her belief that PRO data is increasingly seen as important by payers for validating health claims from a patient perspective. She also mentions both the EU HTA community and US Federal government calling for …

Download: A Pharma Prospective On CER And How It Can Aid Payer Coverage Policies

At Market Access USA 2013, Keith Huff, PharmD, MS gave a presentation on “A Pharma Prospective On Comparative Effectiveness Research And How It Can Aid Payer Coverage Policies” Download the presentation to learn: Needs of the Payer Needs of Pharma Comparative Effectiveness Research How is CER used Needs for credible CER studies Challenges in CER Research Comparing types of data …

Download Ebook: 5 breakthrough therapies to watch

The US FDA’s Breakthrough Therapy demands sufficient preliminary clinical evidence to prove a compelling proof-of-concept; for instance the drug must show substantial improvement on a significant clinical endpoint when compared with current therapies. If these criteria are met, the US FDA is able to expedite the development and review of drug candidates that are able to treat serious of life …

Download: Payer Engagement and Preparing Information to Support Value Proposition

Demonstrate value and improve payer engagement with tips from Jorge Arellano, MSc, MPhil, Director Global Health Economics, Amgen. In his presentation, given at Evidence USA 2013, he discusses these topics and more. Download to learn: Evidence Generation: The Process Evidence Generation: Key Deliverables Payers input Understanding Your Payer(s) Download presentation Discover how pharma, payers and patients are utilizing real world …